Heart failure & cardiomyopathies
Incident Heart Failure is Common and Underrecognized in Patients with Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease
Authors' conclusion
We found a high incidence of HF in patients with biopsy-proven MASLD. Despite nearly half of patients having suspected HF, very few carried a chart diagnosis.
Study context
- Population
- Patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD), Duke NAFLD Biorepository, biopsy 2007–2013560 assessed for incident heart failure (HF)
- Participants
- 570 patients
- Outcome
- Incident HF (HF hospitalization, chart diagnosis, ≥1 sign/symptom with elevated natriuretic peptide, or diastolic dysfunction on echocardiography with ≥1 sign/symptom)
- Follow-up
- Median 4009 days (11.0 years)
Methodological detailssingle-cohort, biopsy-proven MASLD
- Single-cohort
- Biopsy-proven MASLD
Main finding
As reported in the abstract
Incident HF · median 11.0 years
Incident HF
100
17.9%
Met criteria for HF suspicion
268
47.9%
Increasing age associated with incident HF
multivariable OR 1.05
95% CI 1.02–1.08p < 0.001
Female sex associated with incident HF
multivariable OR 1.85
95% CI 1.12–3.04p = 0.02
Observational data: associations, not effects.
Further findings
- Baseline HF
- 10 (1.8%)
Original publication
Incident Heart Failure is Common and Underrecognized in Patients with Biopsy-Proven Metabolic Dysfunction-Associated Steatotic Liver Disease. Eur J Heart Fail. Published 19 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →